ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is a fixed-dose oral tablet combination approved in 1968 for malaria treatment and prevention. The product combines two antimalarial agents targeting different parasite stages. This legacy combination therapy addresses both erythrocytic and exoerythrocytic malaria parasites.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), the brand team is likely in defensive positioning with reduced headcount allocation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal hiring momentum for this product line. Working on ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE offers limited career growth potential given the approaching loss of exclusivity and stable market dynamics.
Brand ManagerField Sales Representative
Worked on ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.